| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |